1. Home
  2. NMAI vs KMDA Comparison

NMAI vs KMDA Comparison

Compare NMAI & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NMAI

Nuveen Multi-Asset Income Fund of Beneficial Interest

HOLD

Current Price

$14.13

Market Cap

458.6M

Sector

Finance

ML Signal

HOLD

Logo Kamada Ltd.

KMDA

Kamada Ltd.

HOLD

Current Price

$7.16

Market Cap

460.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMAI
KMDA
Founded
2021
1990
Country
United States
Israel
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
458.6M
460.3M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
NMAI
KMDA
Price
$14.13
$7.16
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$14.00
AVG Volume (30 Days)
85.7K
31.2K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
13.14%
3.08%
EPS Growth
N/A
N/A
EPS
0.64
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$13.94
Revenue Next Year
N/A
$9.84
P/E Ratio
$21.86
$24.59
Revenue Growth
N/A
N/A
52 Week Low
$11.99
$6.50
52 Week High
$14.38
$9.35

Technical Indicators

Market Signals
Indicator
NMAI
KMDA
Relative Strength Index (RSI) 58.26 52.53
Support Level $13.60 $6.97
Resistance Level $14.30 $7.33
Average True Range (ATR) 0.23 0.15
MACD 0.01 0.03
Stochastic Oscillator 82.64 85.71

Price Performance

Historical Comparison
NMAI
KMDA

About NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest

Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund's investment objective is to provide total return through high current income and capital appreciation.

About KMDA Kamada Ltd.

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Share on Social Networks: